




ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA
DIPARTIMENTO DI
SCIENZE MEDICHE E CHIRURGICHE



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Ospedaliero - Universitaria di Bologna

Policlinico S. Orsola-Malpighi

International Symposium on:
**FROM GOUT TO
CARDIOVASCULAR DISEASE:
A CENTRAL ROLE FOR
URIC ACID**

Bologna (Italy), November 6th - 8th, 2014

Organized by

UNITÀ OPERATIVA MEDICINA INTERNA
AZIENDA OSPEDALIERO – UNIVERSITARIA S. ORSOLA-MALPIGHI
ALMA MATER STUDIORUM UNIVERSITÀ DI BOLOGNA, ITALY

DEPARTMENT OF RHEUMATOLOGY
HÔPITAL LARIBOISIÈRE, PARIS, FRANCE

Promoted by



FONDAZIONE
INTERNAZIONALE
MENARINI

FINAL PROGRAM

Salone Bolognini - Convento S. Domenico (Piazza San Domenico, 13)
Salone Imperiale - Royal Hotel Carlton (Via Montebello, 8)



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA
DIPARTIMENTO DI
SCIENZE MEDICHE E CHIRURGICHE



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Ospedaliero - Universitaria di Bologna

Policlinico S. Orsola-Malpighi

International Symposium on:
**FROM GOUT TO
CARDIOVASCULAR DISEASE:
A CENTRAL ROLE FOR
URIC ACID**

Bologna (Italy), November 6th - 8th, 2014

Organized by

UNITÀ OPERATIVA MEDICINA INTERNA
AZIENDA OSPEDALIERO – UNIVERSITARIA S. ORSOLA-MALPIGHI
ALMA MATER STUDIORUM UNIVERSITÀ DI BOLOGNA, ITALY

DEPARTMENT OF RHEUMATOLOGY
HÔPITAL LARIBOISIÈRE, PARIS, FRANCE

Promoted by



FONDAZIONE
INTERNAZIONALE
MENARINI

FINAL PROGRAM

Salone Bolognini - Convento S. Domenico (Piazza San Domenico, 13)
Salone Imperiale - Royal Hotel Carlton (Via Montebello, 8)

The role of serum uric acid as a risk factor for CV disease has been extensively debated for many years without reaching a final agreement among clinicians and researchers. In particular, most of the evidence about the pathogenetic role of uric acid in CV disease have been achieved in the population of patients with severe hyperuricemia or gout while its role in patients with mildly elevated serum levels of uric acid is only poorly recognized. Serum uric acid represents an important, independent risk factor for cardiovascular and renal disease in patients with hypertension, heart failure, or diabetes. Elevated serum uric acid is highly predictive of mortality in patients with heart failure or coronary artery disease and of cardiovascular events in patients with diabetes. Although the mechanism(s) by which uric acid may play a pathogenetic role in cardiovascular disease is still unclear, hyperuricemia is associated with deleterious effects on endothelial dysfunction, oxidative metabolism, platelet adhesiveness, hemorheology, and aggregation. Whether a reduction in uric acid impacts CV and renal disease remains to be determined. However, recent findings from LIFE suggest the possibility that a treatment-induced decrease in serum uric acid may indeed attenuate cardiovascular risk. Clearly, randomized clinical trials are needed to investigate further the long-term cardioprotective benefits issue of reducing hyperuricemia in hypertensive patients.

The main purpose of the present symposium is twofold. First of all to reinforce the role of uric acid in the pathogenesis of gout and gout-related non-rheumatic diseases including renal involvement. Second to provide an updated review of the evidence supporting a possible and relevant role of (elevated) uric acid as a risk factor for cardiovascular diseases. To fulfill this goal we will present a series of comprehensive lectures mainly focused on the different aspects of the relationship between serum uric acid and cardiovascular diseases with the aim to define whether or not the increase in the amount of our knowledge about uric acid may improve the presenting of CV disease.

*Co-Presidents of the Meeting
Claudio Borghi and Thomas Bardin*

Under the Auspices of

Dipartimento di Scienze Mediche e Chirurgiche,
Alma Mater Studiorum Università di Bologna
Major of the City of Bologna
European Society of Hypertension
Italian Society of Hypertension
Italian Society of Rheumatology

Co-Presidents of the Meeting

Claudio Borghi

U.O. Medicina Interna
Azienda Ospedaliero
Universitaria di Bologna
Policlinico S. Orsola – Malpighi
Alma Mater Studiorum
Università di Bologna - Bologna (Italy)

Thomas Bardin

Department of Rheumatology
Hôpital Lariboisière
Paris (France)

Scientific Secretariat

Elisa Rossi

Azienda Ospedaliero - Universitaria
di Bologna
Policlinico S. Orsola - Malpighi
Bologna (Italy)

Arrigo F.G. Cicero

Alma Mater Studiorum
Università di Bologna
Bologna (Italy)

Promoted by

Fondazione Internazionale Menarini

Edificio L - Strada 6
Centro Direzionale Milanofiori
I-20089 Rozzano (Milan, I)
Phone: +39 02 55308110 - Fax: +39 02 55305739
E-mail: milan@fondazione-menarini.it
[Http://www.fondazione-menarini.it](http://www.fondazione-menarini.it)

Organizing Secretariat and Provider for Italian CME accreditation

I&C s.r.l.

Via Andrea Costa, 202/6
I-40134 Bologna (Italy)
Phone: +39 051 6144004
Fax: +39 051 6142772
E-mail: federica.schiassi@iec-srl.it
sara.galeotti@iec-srl.it

Opening ceremony

06.00 p.m. **Welcome addresses**

T. Bardin (Paris, F)

C. Borghi (Bologna, I)

06.15 p.m. *Introduction:* **E. Ambrosioni** (Bologna, I)

A.M. Heagerty (Manchester, UK)

Main Lecture

R.J. Johnson (Denver, USA)

Serum Uric Acid and cardiovascular risk: why not?

07.00 p.m. Welcome cocktail

**Session I Serum Uric Acid and Gout:
from the human evolution to mechanism of disease**

Chairpersons: **T. Bardin** (Paris, F)
A. K. Tausche (Dresden, D)

09.00 a.m. **G. Fornaciari** (Pisa, I)
Ancient heart disease and uric acid

09.30 a.m. **L.F. Perez-Ruiz** (Vizcaya, E)
Biochemistry of Uric Acid in clinical perspective

10.00 a.m. **C. Ferri** (L'Aquila, I)
Uric acid: from molecular mechanisms to
human vascular damage

10.30 a.m. **M.A. Becker** (Chicago, USA)
The role of inflammasome between uric acid and gout

11.00 a.m. *Coffee break*

Session II Genetic of serum uric acid, gout and cardio-renal disease

Chairpersons: **A. Pfeufer** (Munich, D)
A. Stack (Limerick, IRL)

11.30 a.m. **R. Torres Jiménez** (Madrid, E)
Genetics of gout

12.00 a.m. **J. Dawson** (Glasgow, UK)
Genes, uric acid and CV diseases

12.30 a.m. **J.T. Kielstein** (Hannover, D)
Genes, uric acid and the kidney

01.00 p.m. *Lunch*

Session III How to manage the patients with gout

Chairpersons: **M.H. Alderman** (New York, USA)
G. Minisola (Rome, I)

02.00 p.m. **P. Richette** (Paris, F)
The interaction between gout and other rheumatic diseases:
current trends

02.30 p.m. **L. Punzi** (Padua, I)
Urate cristal deposition and gout: epidemiology and clinical
evidence

03.00 p.m. **J.G. Puig** (Madrid, E)
Diagnosis of gout in patients with asymptomatic
hyperuricemia

03.30 p.m. **T. Bardin** (Paris, F)
The management of gout in the era of guidelines

04.00 p.m. *Coffee break*

Session IV Serum uric acid, gout and hypertension

Chairpersons: **G. Mancia** (Milan, I)
M. Volpe (Rome, I)

04.30 p.m. **M. Mazzali** (Campinas, BR)
Uric acid in the development of hypertension:
experimental data

05.00 p.m. **C. Borghi** (Bologna, I)
Uric acid and hypertensive disease: epidemiological data

05.30 p.m. **G. Grassi** (Monza, I)
Serum uric acid and blood pressure profile

06.00 p.m. **R. Cifkova** (Prague, CZ)
Management of serum uric acid and prevention
of hypertension

Session V Uric acid and cardiovascular diseases: the evidence

Chairpersons: **G. McCarthy** (Dublin, IRL)
R. Pontremoli (Genoa, I)

09.00 a.m. **A. Stack** (Limerick, IRL)
Uric acid, gout and CV disease: which evidence?

09.30 a.m. **S. Taddei** (Pisa, I)
The mechanisms of vascular involvement in patients with hyperuricemia

10.00 a.m. **A.J. Manolis** (Athens, GR)
Serum uric acid and atrial fibrillation: epidemiology and mechanism of disease

10.30 a.m. **E. Ritz** (Heidelberg, D)
Hyperuricemia and CV disease: the role of renal impairment

11.00 a.m. *Coffee break*

Session VI The management of hyperuricemia beyond the gout

Chairpersons: **E. Agabiti-Rosei** (Brescia, I)
A.J. Manolis (Athens, GR)

11.30 a.m. **A. Morganti** (Milan, I)
Is there anything good in uric acid?

12.00 a.m. **G.B. Desideri** (L'Aquila, I)
Serum uric acid, stroke, and cognitive function

12.30 a.m. **D.I. Feig** (Birmingham, USA)
Can we affect the CV diseases by managing serum uric acid?

01.00 p.m. **Final session - Hyperuricemia and Pharmacoeconomic aspects****
E. Ambrosioni (Bologna, I), **C. Borghi** (Bologna, I),
G.B. Desideri (L'Aquila, I)

01.20 p.m. Concluding Remarks

**not included in the CME program

GENERAL INFORMATION

Meeting venues

The venues for the Meeting will be:

- November 6th, *Salone Bolognini - Convento S. Domenico*
(Piazza San Domenico, 13 – Bologna, Italy)

- November 7th – 8th, *Salone Imperiale - Royal Hotel Carlton*
(Via Montebello, 8 – Bologna, Italy)

Secretariat during the Meeting

The Secretariat will be open at the following times:

Thursday, November 6th, from 05.00 p.m. to 07.00 p.m.

Friday, November 7th, from 08.00 a.m. to 06.00 p.m.

Saturday, November 8th, from 08.00 a.m. to 01.30 p.m.

Official language

The official language of the Meeting will be English.

Registration

The Meeting is free to attend.

Italian CME Accreditation

The Meeting has obtained 5.5 CME Italian credits for Italian Physicians for the following specialties: Nurse, Physician and Surgeon (Cardiology, Internal Medicine, Diabetology, Nephrology, Endocrinology, Neurology, Clinical Biochemistry, Hygiene), Pharmacist.

The CME credits will be recognized only after full attendance of all sessions and a minimum score of 75% of correct answers in the learning questionnaires.

Completion of the Registration Form, the Learning & Assessment questionnaires are compulsory.

For information on European Accreditation, please see next page

An application has been made to the EACCME and EBAC for CME accreditation of this event.

Technical facilities

Facilities will be available for computer presentations and overhead projections.

A slide center with PC (Powerpoint for Windows) will be available for check and preview of presentations. It is essential that speakers take their presentation to the slide center at least one hour before the session starts.

The slide center will be open at the following times:

Thursday, November 6th, from 05.00 p.m. to 07.00 p.m.

Friday, November 7th, from 08.00 a.m. to 06.00 p.m.

Saturday, November 8th, from 08.00 a.m. to 01.30 p.m.

Lunches and coffee breaks

Lunches and coffee breaks will be served in the Meeting area.

Abstracts book

Participants will receive the Abstract book at the Meeting.

Certificate of attendance

The certificate of attendance will be available, on request, at the end of the Meeting at the Secretariat.



EBAC ACCREDITATION

The event “**International Symposium on: “From gout to cardiovascular disease: a central role for uric acid”** (Ref. 00003305), is accredited by the European Board for Accreditation in Cardiology (EBAC) for **11 hours of External CME credits**. (Day #1: 1 CME credit - Day #2: 6 CME credits - Day #3: 4 CME credits)

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed potential conflicts of interest that might cause a bias in the presentations. The Organising Committee is responsible for ensuring that all potential conflicts of interest relevant to the programme are declared to the audience prior to the CME activities.

LEARNING OBJECTIVES AND TARGET AUDIENCE

The main purpose of this second Bologna symposium on Serum Uric Acid and Cardiovascular disease is to enlarge the view on this topic by discussing in great details and with the support of several distinguished scientists the many aspects of the pathophysiological mechanisms involved in the development of the CV disease associated with elevated levels of serum uric acid in patients with and without gout. We will also put some emphasis in the review of the available therapeutic evidence as well as in the interaction between the mechanism of action of the different drugs involved in the management of uric acid with the aim to stimulate the future research in a very “innovative” and challenging field that may be strategic for the prevention of cardiovascular disease in the very next future.

The symposium is addressed to **Physicians** (Cardiology, Internal Medicine, Diabetology, Nephrology, Endocrinology, Neurology) **Nurses** and **Pharmacists**.

CME PROVIDER

DIMES Department

Alma Mater Studiorum University of Bologna

COURSE BOARDING DIRECTORS

Claudio Borghi

Thomas Bardin

LIST OF SPEAKERS, CHAIRPERSONS AND CO-PRESIDENTS OF THE MEETING

Enrico AGABITI-ROSEI

Dipartimento di Scienze Mediche e Chirurgiche
II Divisione di Medicina
Università degli Studi di Brescia
Spedali Civili
Brescia (Italy)

Michael H. ALDERMAN

Department of Epidemiology and Population Health
Albert Einstein College of Medicine
Yeshiva University
New York (USA)

Ettore AMBROSIONI

Società Italiana dell'Ipertensione Arteriosa
Clinica Medica
Università di Bologna
Bologna (Italy)

Thomas BARDIN

Department of Rheumatology
Hôpital Lariboisière
Paris (France)

Michael A. BECKER

Department of Medicine
University of Chicago
Chicago (USA)

Claudio BORGHI

UO Medicina Interna
Azienda Ospedaliero-Universitaria di Bologna
Policlinico S. Orsola-Malpighi
Alma Mater Studiorum Università di Bologna
Bologna (Italy)

Renata CIFKOVA

Center for Cardiovascular Prevention
Charles University in Prague
First Faculty of Medicine and Thomayer Hospital
Prague (Czech Republic)

Jesse DAWSON

Institute of Cardiovascular and Medical Sciences
University of Glasgow Western Infirmary
Glasgow (United Kingdom)

Giovambattista DESIDERI

UOC Geriatria e Lungodegenza
Dipartimento Medico ORM
Università degli Studi de L'Aquila
PO San Filippo e Nicola di Avezzano
L'Aquila (Italy)

Daniel I. FEIG

Department of Pediatrics
Division of Nephrology
University of Alabama
Birmingham and Children's of Alabama
Birmingham (USA)

Claudio FERRI

Division of Internal Medicine & Nephrology
and School of Internal Medicine
University of L'Aquila
San Salvatore Hospital
Coppito (L'Aquila, Italy)

Gino FORNACIARI

Division of Palaeopathology
Department of Oncology, Transplants
and Modern Technologies in Medicine
University of Pisa
Pisa (Italy)

Guido GRASSI

Dipartimento Scienze della Salute
Clinica Medica
Università Milano-Bicocca
Ospedale San Gerardo
Monza (MB, Italy)

Anthony M. HEAGERTY

Institute of Cardiovascular Sciences
The University of Manchester
Manchester (United Kingdom)

Richard J. JOHNSON

Division of Renal Diseases and Hypertension
University of Colorado
Anschutz Medical Campus
Denver (USA)

Jan T. KIELSTEIN

Department of Nephrology and Hypertension
Hannover Medical School
Hannover (Germany)

Giuseppe MANCIA

Department of Health Sciences
University of Milano-Bicocca
Milan (Italy)

Athanasios MANOLIS

Department of Cardiology
Hospital of Asklepeion
Athens (Greece)

Marilda MAZZALI

Division of Nephrology
Department of Medicine
State University of Campinas
Campinas (Brazil)

Geraldine McCARTHY

Rheumatology Division
Mater Misericordiae University Hospital
Dublin (Ireland)

Giovanni MINISOLA

Unità Operativa Complessa di Reumatologia
Ospedale di Alta Specializzazione San Camillo
Rome (Italy)

Alberto MORGANTI

U.O. di Medicina Interna
Centro Ipertensione Arteriosa
Ospedale San Giuseppe
Università di Milano
Milan (Italy)

Fernando PEREZ RUIZ
Rheumatology Division
Cruces University Hospital
Vizcaya (Spain)

Arne PFEUFER
Department of Bioinformatics and Systems Biology
Helmholz Zentrum Munich
Munich (Germany)

Roberto PONTREMOLI
Dipartimento di Medicina Interna
e Specialità Mediche (DIMI)
Università degli Studi di Genova
Genoa (Italy)

Juan Garcia PUIG
Facultad de Medicina
Universidad Autónoma de Madrid (UAM)
Madrid (Spain)

Leonardo PUNZI
Rheumatology Unit
Department of Medicine
Medical School
University of Padua
Padua (Italy)

Pascal RICHETTE
Department of Rheumatology
Hôpital Lariboisière
Paris (France)

Eberhard RITZ
Department of Nephrology
Nierenzentrum
Heidelberg (Germany)

Austin STACK
Department of Nephrology
University Hospital Limerick
Limerick (Ireland)

Stefano TADDEI

Dipartimento di Medicina Interna
Università degli Studi di Pisa
Pisa (Italy)

Anne-Kathrin TAUSCHE

Clinical Trial Unit Division of Rheumatology
University Hospital “Carl Gustav Carus”
Dresden (Germany)

Rosa TORRES JIMENEZ

Laboratorio Hiperuricemias congénitas
Unidad Metabólico Vascular
Universidad Autónoma de Madrid (UAM)
Madrid (Spain)

Massimo VOLPE

Cardiology Unit
Department of Cardiothoracic and Vascular Science
Faculty of Medicine and Psychology
Sapienza University of Roma
Rome (Italy)

A Special Thank to

**LABORATORIOS MENARINI SPAIN
MENARINI FRANCE
MENARINI I.F.R.
MENARINI INTERNATIONAL O.L.**

for not conditioning financial support

[illegible]

